Core Viewpoint - Tonghua Dongbao (600867.SH) has announced a share buyback program, indicating a commitment to returning value to shareholders through capital management strategies [1] Summary by Categories Share Buyback Details - As of December 31, 2025, the company has repurchased a total of 3 million shares, which represents 0.15% of the current total share capital [1] - The highest transaction price for the repurchased shares was 9.33 yuan per share, while the lowest was 9.00 yuan per share [1] - The total amount spent on the share buyback, excluding transaction fees, is 27,574,286.00 yuan [1]

关于以集中竞价交易方式回购公司股份进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/10/18，由董事长李佳鸿提议 | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 2025 17 4 | 10 | 月 | 日~2026 | 年 | 月 | 日 16 | | 预计回购金额 | 2,000万元~4,000万元 | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 □用于转换公司可转债 | | | | | | | | | □为维护公司价值及股东权益 | | | | | | | | 累计已回购股数 | 3,000,000股 | | | | | | | | 累计已回购股数占总股本比例 | 0.15% | | | | | | | | 累计已回购金额 | 27,574,286.00元 | | | | | | | | 实际回购价格区间 ...

Core Viewpoint - The biopharmaceutical sector experienced a slight decline of 0.34% on December 30, with Wanze Co., Ltd. leading the losses. The Shanghai Composite Index closed at 3965.12, down 0.0%, while the Shenzhen Component Index rose by 0.49% to 13604.07 [1]. Group 1: Market Performance - The biopharmaceutical sector's performance showed mixed results, with individual stocks experiencing varying degrees of gains and losses. Notably, Aidi Pharmaceutical saw a rise of 4.10% to close at 15.98, while Wanze Co., Ltd. fell by 6.76% to 21.94 [1][2]. - The trading volume for Aidi Pharmaceutical was 93,900 shares, with a transaction value of 150 million yuan, indicating strong investor interest [1]. Group 2: Capital Flow - The biopharmaceutical sector faced a net outflow of 330 million yuan from institutional investors, while retail investors contributed a net inflow of 349 million yuan, suggesting a shift in investor sentiment [2]. - The data indicates that while institutional investors withdrew funds, retail investors were more active in purchasing shares within the sector [2][3]. Group 3: Individual Stock Analysis - Ganne Pharmaceutical experienced a net outflow of 34.73 million yuan from institutional investors, while retail investors showed a net inflow of 129.36 million yuan, reflecting a divergence in investment strategies [3]. - Other notable stocks included Huashan Biological, which had a net inflow of 430.99 million yuan from institutional investors, indicating positive sentiment towards its performance [3].

证券代码：600867 证券简称：通化东宝 公告编号：2025-087 通化东宝药业股份有限公司 关于控股股东股份解押及再质押公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示: 通化东宝药业股份有限公司（以下简称"公司"或"本公司"）控股股东东 宝实业集团股份有限公司（以下简称"东宝集团"）及其一致行动人合计持有公 司股份 641,362,975 股，占公司目前股份总额的 32.75%；东宝集团及其一致行 动人持有公司股份累计质押数量（本次解押及再质押后）为 562,439,472 股，占 其及一致行动人所持有公司股份总额的 87.69%，占公司目前股份总额的 28.72%。 其中：东宝集团持有公司股份 619,500,796 股，占公司目前股份总额的 31.63%， 东宝集团持有公司股份累计质押数量（本次解押及再质押后）为 562,439,472 股， 占其所持有公司股份总额的 90.79%，占公司目前股份总额的 28.72%。 2025 年 12 月 30 日,本公司接到东宝集团关于股份解押及再质押相关情 ...

Group 1 - The company has approved the implementation of the R&D Production System Employee Stock Ownership Plan (ESOP) during the board meeting on November 28, 2025, and the extraordinary shareholders' meeting on December 15, 2025 [1] - The ESOP involves the transfer of 6.37 million shares at a price of 4.39 yuan per share, which represents 0.325% of the company's total share capital [1] - The company has received confirmation from the China Securities Depository and Clearing Corporation regarding the stock transfer to the ESOP [1] Group 2 - The ESOP has a duration of 60 months, starting from the date of the last stock transfer to the plan [2] - The stock will be unlocked in three phases: 40% after 12 months, 30% after 24 months, and 30% after 36 months, with actual unlock ratios based on performance assessments [2] - The company will monitor the implementation of the ESOP and fulfill its information disclosure obligations as required [2]

Core Viewpoint - Tonghua Dongbao (600867) is currently in the preclinical research phase for its insulin weekly formulation, with future research progress to be disclosed according to relevant regulations and requirements [1] Group 1 - The company has a strategic focus on developing insulin weekly formulations [1] - The research is currently at the preclinical stage, indicating ongoing development efforts [1] - The company will provide updates on research progress through regular reports and announcements [1]

Core Viewpoint - Tonghua Dongbao (600867) reported strong sales performance for its drug, Englitazone, with over 100% year-on-year growth in sales for the first three quarters of the year [1] Group 1 - The company indicated that the sales situation for Englitazone was good in both the first half and the third quarter of the year [1] - The sales revenue for the first three quarters exceeded 100% growth compared to the previous year [1]

Group 1 - The company, Tonghua Dongbao, has four innovative drugs in clinical trials, with two in the GLP-1 category and two for gout treatment [2]

Group 1 - The core viewpoint of the article is that Tonghua Dongbao reported strong sales performance for its drug, Englitazone, in the first half of the year and the third quarter, with a year-on-year sales growth exceeding 100% in the first three quarters [1] Group 2 - The company responded to an investor inquiry on an interactive platform regarding the sales situation of Englitazone [1] - The sales figures indicate a significant increase, reflecting the company's strong market performance [1] - The report highlights the company's positive trajectory in sales, which may indicate potential growth opportunities in the pharmaceutical sector [1]

Core Viewpoint - The company is currently engaged in the development of insulin depot formulations and is in the preclinical research stage for its fourth-generation insulin products [1] Group 1 - The company has received inquiries from investors regarding its plans for fourth-generation insulin depot formulations [1] - The company confirmed that it has relevant research and development activities in insulin depot formulations [1] - Future research and development progress will be disclosed in accordance with relevant regulations and requirements [1]